本文へ移動
cccskills
無料GitHub で公開

es-cushing-glucocorticoid-antagonist-diabetes-glucose-intolerance

This skill suggests administering a glucocorticoid antagonist (e.g., mifepristone) in patients with Cushing's disease who have diabetes or glucose intolerance and are not surgical candidates or have persistent disease after transsphenoidal surgery. Consider when encountering persistent hypercortisolism after TSS, contraindications to surgery, or comorbid diabetes/glucose intolerance requiring medical control.

dromlakhani/MD2SKILL
インストール方法を見る

含まれるファイル（1）

  • SKILL.md2.7 KB

SKILL.md（原文）

インストールする前に、エージェントに与えられる指示の中身を確認できます。

Glucocorticoid Antagonist in Patients With Diabetes or Glucose Intolerance Who Are Not Surgical Candidates or Have Persistent Disease After TSS

STEP 1 — Gather Information

Confirm ACTH-dependent Cushing's disease (CD) via biochemical testing (elevated UFC, lack of suppression on dexamethasone). Assess diabetes/glucose intolerance (HbA1c ≥6.5%, fasting glucose ≥126 mg/dL, or 2‑h OGTT ≥200 mg/dL). Determine surgical candidacy (review comorbidities, prior TSS outcomes, patient preference). If postoperative, obtain latest serum cortisol or UFC to document persistence.

STEP 2 — Rule In / Rule Out

Is the patient NOT a surgical candidate OR does the patient have persistent hypercortisolism after TSS? If YES, proceed to Step 3. If NO, consider first‑line surgery or other second‑line options per guideline.

STEP 3 — Classify or Stratify

Does the patient have diabetes or glucose intolerance? If YES, proceed to Step 4. If NO, consider alternative medical therapy (e.g., steroidogenesis inhibitors) per 6.4a.

STEP 4 — Decide

Administer a glucocorticoid antagonist (mifepristone). Start at 300 mg daily, titrate upward based on clinical response (glucose, weight, blood pressure) up to 1200 mg/day as needed. Monitor for adrenal insufficiency clinically (fatigue, nausea, hypotension) and avoid relying on cortisol levels for efficacy assessment.

Clinical Guardrails / Mimics / Pitfalls

Do not use in pregnancy (abortifacient risk). Watch for hypokalemia, hypertension, edema, and endometrial thickening; correct hypokalemia before and during therapy. Do not rely on UFC or serum cortisol to guide dose; efficacy is assessed via glucose, weight, and blood pressure. Avoid in patients with known adrenal insufficiency unless glucocorticoid replacement is planned.

Concrete Clinical Example

A 48‑year‑old woman with recurrent CD after TSS, HbA1c 8.1%, not a surgical candidate due to severe COPD, started mifepristone 300 mg daily. Titrated to 600 mg daily over 4 weeks; HbA1c improved to 7.0%, weight decreased 4 kg, blood pressure improved, with no signs of adrenal insufficiency.

Source: Treatment of Cushing’s Syndrome: An Endocrine Society Clinical Practice Guideline, Nieman et al., 2015, DOI:10.1210/jc.2015-1818

レビュー

まだレビューはありません。使ってみた感想をお寄せください。

ログインしてレビューを書く

同じリポジトリのスキル

概要と使いどころ

780g-pump-adjustment

無料

Guide pump setting adjustments for the MiniMed 780G system based on CareLink data, using Medtronic's 3-step follow-up workflow. Use when a clinician has CareLink data for a 780G patient and wants to know what to change — which setting, by how much, and how to program it. Triggers include: "what do I adjust", "how to fix high TIR", "how to reduce hypos", "adjust ICR/ISF/basal", "SmartGuard settings", "780G pump settings review", or any question about optimising 780G therapy after reviewing a download.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

ata-acth-stim-test-interpretation

無料

Performs corticotropin stimulation test to diagnose adrenal insufficiency when morning cortisol is indeterminate (3-15 µg/dL). Triggers include morning cortisol 3-15 µg/dL requiring further AI testing.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

ata-adrenal-crisis-treatment

無料

Administers immediate parenteral injection of 50–100 mg hydrocortisone for suspected adrenal crisis secondary to adrenal insufficiency. Triggers include hypotension, hypoglycemia, or acute illness in a patient with known adrenal insufficiency.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

ata-aed-ai-education

無料

Clinicians educate adrenal insufficiency patients taking nondexamethasone glucocorticoids who initiate enzyme-inducing antiepileptic drugs about early signs of adrenal insufficiency. Trigger when an AI patient on nondexamethasone GC starts an enzyme-inducing AED such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

ata-aed-lt4-monitoring

無料

In central hypothyroidism patients receiving levothyroxine who initiate enzyme‑inducing antiepileptic drugs, the guideline recommends checking free T4 at least 6 weeks after AED start and increasing the levothyroxine dose if free T4 falls below the target range. Triggers include: central hypothyroidism patient on levothyroxine starting antiepileptic drug such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

ata-cortisol-cutoff-ai-diagnosis

無料

Applies serum cortisol cutoffs (<3 μg/dL indicates central adrenal insufficiency; >15 μg/dL likely excludes it) when evaluating morning cortisol for suspected adrenal insufficiency. Triggers include morning cortisol measurement in suspected AI and use when interpreting morning cortisol levels for adrenal insufficiency workup.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

dromlakhani のスキルをすべて見る

このスキルの問題を報告する